Skip to main content
Erschienen in: Pediatric Nephrology 11/2020

15.06.2020 | Original Article

Corticosteroids to prevent kidney scarring in children with a febrile urinary tract infection: a randomized trial

verfasst von: Nader Shaikh, Timothy R. Shope, Alejandro Hoberman, Gysella B. Muniz, Sonika Bhatnagar, Andrew Nowalk, Robert W. Hickey, Marian G. Michaels, Diana Kearney, Howard E. Rockette, Martin Charron, Ruth Lim, Massoud Majd, Eglal Shalaby-Rana, Marcia Kurs-Lasky, Daniel M. Cohen, Ellen R. Wald, Greg Lockhart, Hans G. Pohl, Judith M. Martin

Erschienen in: Pediatric Nephrology | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

To evaluate the efficacy of adjuvant systemic corticosteroids in reducing kidney scarring. A previous study suggested that use of adjuvant systemic corticosteroids reduces kidney scarring in children radiologically confirmed to have extensive pyelonephritis. Efficacy of corticosteroids for children with febrile urinary tract infection (UTI) has not been studied.

Methods

Children aged 2 months to 6 years with their first febrile UTI were randomized to corticosteroids or placebo for 3 days (both arms received antimicrobial therapy); kidney scarring was assessed using 99mTc-dimercaptosuccinic acid kidney scan 5–24 months after the initial UTI.

Results

We randomized 546 children of which 385 had a UTI and 254 had outcome kidney scans (instead of the 320 planned). Rates of kidney scarring were 9.8% (12/123) and 16.8% (22/131) in the corticosteroid and placebo groups, respectively (p = 0.16), corresponding to an absolute risk reduction of 5.9% (95% confidence interval: − 2.2, 14.1).

Conclusion

While children randomized to adjuvant corticosteroids tended to develop fewer kidney scars than children who were randomized to receive placebo, a statistically significant difference was not achieved. However, the study was limited by not reaching its intended sample size.

Clinical Trial Registration

Clinicaltrials.​gov, NCT01391793, Registered 7/12/2011
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wennerstrom M, Hansson S, Jodal U, Sixt R, Stokland E (2000) Renal function 16 to 26 years after the first urinary tract infection in childhood. Arch Pediatr Adolesc Med 154:339–345CrossRef Wennerstrom M, Hansson S, Jodal U, Sixt R, Stokland E (2000) Renal function 16 to 26 years after the first urinary tract infection in childhood. Arch Pediatr Adolesc Med 154:339–345CrossRef
2.
Zurück zum Zitat Wennerstrom M, Hansson S, Hedner T, Himmelmann A, Jodal U (2000) Ambulatory blood pressure 16-26 years after the first urinary tract infection in childhood. J Hypertens 18:485–491CrossRef Wennerstrom M, Hansson S, Hedner T, Himmelmann A, Jodal U (2000) Ambulatory blood pressure 16-26 years after the first urinary tract infection in childhood. J Hypertens 18:485–491CrossRef
3.
Zurück zum Zitat Martinell J, Lidin-Janson G, Jagenburg R, Sivertsson R, Claesson I, Jodal U (1996) Girls prone to urinary infections followed into adulthood. Indices of renal disease. Pediatr Nephrol 10:139–142CrossRef Martinell J, Lidin-Janson G, Jagenburg R, Sivertsson R, Claesson I, Jodal U (1996) Girls prone to urinary infections followed into adulthood. Indices of renal disease. Pediatr Nephrol 10:139–142CrossRef
4.
Zurück zum Zitat Jacobson SH, Eklof O, Eriksson CG, Lins LE, Tidgren B, Winberg J (1989) Development of hypertension and uraemia after pyelonephritis in childhood: 27 year follow up. BMJ 299:703–706CrossRef Jacobson SH, Eklof O, Eriksson CG, Lins LE, Tidgren B, Winberg J (1989) Development of hypertension and uraemia after pyelonephritis in childhood: 27 year follow up. BMJ 299:703–706CrossRef
5.
Zurück zum Zitat Haraoka M, Matsumoto T, Mizunoe Y, Ogata N, Takahashi K, Kubo S, Tanaka M, Kumazawa J (1993) Effect of prednisolone on renal scarring in rats following infection with Serratia marcescens. Ren Fail 15:567–571CrossRef Haraoka M, Matsumoto T, Mizunoe Y, Ogata N, Takahashi K, Kubo S, Tanaka M, Kumazawa J (1993) Effect of prednisolone on renal scarring in rats following infection with Serratia marcescens. Ren Fail 15:567–571CrossRef
6.
Zurück zum Zitat Haraoka M, Matsumoto T, Takahashi K, Kubo S, Tanaka M, Kumazawa J (1994) Suppression of renal scarring by prednisolone combined with ciprofloxacin in ascending pyelonephritis in rats. J Urol 151:1078–1080CrossRef Haraoka M, Matsumoto T, Takahashi K, Kubo S, Tanaka M, Kumazawa J (1994) Suppression of renal scarring by prednisolone combined with ciprofloxacin in ascending pyelonephritis in rats. J Urol 151:1078–1080CrossRef
7.
Zurück zum Zitat Hoberman A, Wald ER, Hickey RW, Baskin M, Charron M, Majd M, Kearney DH, Reynolds EA, Ruley J, Janosky JE (1999) Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 104:79–86CrossRef Hoberman A, Wald ER, Hickey RW, Baskin M, Charron M, Majd M, Kearney DH, Reynolds EA, Ruley J, Janosky JE (1999) Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 104:79–86CrossRef
8.
Zurück zum Zitat Huang A, Palmer LS, Hom D, Anderson AE, Kushner L, Franco I (1999) Ibuprofen combined with antibiotics suppresses renal scarring due to ascending pyelonephritis in rats. J Urol 162:1396–1398CrossRef Huang A, Palmer LS, Hom D, Anderson AE, Kushner L, Franco I (1999) Ibuprofen combined with antibiotics suppresses renal scarring due to ascending pyelonephritis in rats. J Urol 162:1396–1398CrossRef
9.
Zurück zum Zitat Meylan PR, Markert M, Bille J, Glauser MP (1989) Relationship between neutrophil-mediated oxidative injury during acute experimental pyelonephritis and chronic renal scarring. Infect Immun 57:2196–2202CrossRef Meylan PR, Markert M, Bille J, Glauser MP (1989) Relationship between neutrophil-mediated oxidative injury during acute experimental pyelonephritis and chronic renal scarring. Infect Immun 57:2196–2202CrossRef
10.
Zurück zum Zitat Omrod D, Cawley S, Miller T (1986) Neutrophil-mediated tissue destruction in experimental pyelonephritis. Univ of Chicago, Chicago Omrod D, Cawley S, Miller T (1986) Neutrophil-mediated tissue destruction in experimental pyelonephritis. Univ of Chicago, Chicago
11.
Zurück zum Zitat Pohl HG, Rushton HG, Park JS, Chandra R, Majd M (1999) Adjunctive oral corticosteroids reduce renal scarring: the piglet model of reflux and acute experimental pyelonephritis. J Urol 162:815–820CrossRef Pohl HG, Rushton HG, Park JS, Chandra R, Majd M (1999) Adjunctive oral corticosteroids reduce renal scarring: the piglet model of reflux and acute experimental pyelonephritis. J Urol 162:815–820CrossRef
12.
Zurück zum Zitat Roberts JA, Roth JK Jr, Domingue G, Lewis RW, Kaack B, Baskin G (1983) Immunology of pyelonephritis in the primate model. VI Effect of complement depletion. J Urol 129:193–196CrossRef Roberts JA, Roth JK Jr, Domingue G, Lewis RW, Kaack B, Baskin G (1983) Immunology of pyelonephritis in the primate model. VI Effect of complement depletion. J Urol 129:193–196CrossRef
13.
Zurück zum Zitat Shimamura T (1981) Mechanisms of renal tissue destruction in an experimental acute pyelonephritis. Exp Mol Pathol 34:34–42CrossRef Shimamura T (1981) Mechanisms of renal tissue destruction in an experimental acute pyelonephritis. Exp Mol Pathol 34:34–42CrossRef
14.
Zurück zum Zitat Calderon-Margalit R, Golan E, Twig G, Leiba A, Tzur D, Afek A, Skorecki K, Vivante A (2018) History of childhood kidney disease and risk of adult end-stage renal disease. N Engl J Med 378:428–438CrossRef Calderon-Margalit R, Golan E, Twig G, Leiba A, Tzur D, Afek A, Skorecki K, Vivante A (2018) History of childhood kidney disease and risk of adult end-stage renal disease. N Engl J Med 378:428–438CrossRef
15.
Zurück zum Zitat Bille J, Glauser MP (1982) Protection against chronic pyelonephritis in rats by suppression of acute suppuration: effect of colchicine and neutropenia. J Infect Dis 146:220–226CrossRef Bille J, Glauser MP (1982) Protection against chronic pyelonephritis in rats by suppression of acute suppuration: effect of colchicine and neutropenia. J Infect Dis 146:220–226CrossRef
16.
Zurück zum Zitat Roberts JA, Roth JK Jr, Domingue G, Lewis RW, Kaack B, Baskin G (1982) Immunology of pyelonephritis in the primate model. V Effect of superoxide dismutase. J Urol 128:1394–1400CrossRef Roberts JA, Roth JK Jr, Domingue G, Lewis RW, Kaack B, Baskin G (1982) Immunology of pyelonephritis in the primate model. V Effect of superoxide dismutase. J Urol 128:1394–1400CrossRef
17.
Zurück zum Zitat Glauser MP, Lyons JM, Braude AI (1978) Prevention of chronic experimental pyelonephritis by suppression of acute suppuration. J Clin Invest 61:403–407CrossRef Glauser MP, Lyons JM, Braude AI (1978) Prevention of chronic experimental pyelonephritis by suppression of acute suppuration. J Clin Invest 61:403–407CrossRef
18.
Zurück zum Zitat Huang YY, Chen MJ, Chiu NT, Chou HH, Lin KY, Chiou YY (2011) Adjunctive oral methylprednisolone in pediatric acute pyelonephritis alleviates renal scarring. Pediatrics 128:e496–e504CrossRef Huang YY, Chen MJ, Chiu NT, Chou HH, Lin KY, Chiou YY (2011) Adjunctive oral methylprednisolone in pediatric acute pyelonephritis alleviates renal scarring. Pediatrics 128:e496–e504CrossRef
19.
Zurück zum Zitat Farhat W, Bagli DJ, Capolicchio G, O'Reilly S, Merguerian PA, Khoury A, McLorie GA (2000) The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children. J Urol 164:1011–1015CrossRef Farhat W, Bagli DJ, Capolicchio G, O'Reilly S, Merguerian PA, Khoury A, McLorie GA (2000) The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children. J Urol 164:1011–1015CrossRef
20.
Zurück zum Zitat Benninga M, Candy DC, Catto-Smith AG, Clayden G, Loening-Baucke V, Di Lorenzo C, Nurko S, Staiano A (2005) The Paris consensus on childhood constipation terminology (PACCT) group. J Pediatr Gastroenterol Nutr 40:273–275CrossRef Benninga M, Candy DC, Catto-Smith AG, Clayden G, Loening-Baucke V, Di Lorenzo C, Nurko S, Staiano A (2005) The Paris consensus on childhood constipation terminology (PACCT) group. J Pediatr Gastroenterol Nutr 40:273–275CrossRef
21.
Zurück zum Zitat Keren R, Carpenter MA, Hoberman A, Shaikh N, Matoo TK, Chesney RW, Matthews R, Gerson AC, Greenfield SP, Fivush B, McLurie GA, Rushton HG, Canning D, Nelson CP, Greenbaum L, Bukowski T, Primack W, Sutherland R, Hosking J, Stewart D, Elder J, Moxey-Mims M, Nyberg L (2008) Rationale and design issues of the randomized intervention for children with Vesicoureteral Reflux (RIVUR) study. Pediatrics 122(Suppl 5):S240–S250CrossRef Keren R, Carpenter MA, Hoberman A, Shaikh N, Matoo TK, Chesney RW, Matthews R, Gerson AC, Greenfield SP, Fivush B, McLurie GA, Rushton HG, Canning D, Nelson CP, Greenbaum L, Bukowski T, Primack W, Sutherland R, Hosking J, Stewart D, Elder J, Moxey-Mims M, Nyberg L (2008) Rationale and design issues of the randomized intervention for children with Vesicoureteral Reflux (RIVUR) study. Pediatrics 122(Suppl 5):S240–S250CrossRef
22.
Zurück zum Zitat Shaikh N, Ewing AL, Bhatnagar S, Hoberman A (2010) Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics 126:1084–1091CrossRef Shaikh N, Ewing AL, Bhatnagar S, Hoberman A (2010) Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics 126:1084–1091CrossRef
23.
Zurück zum Zitat Chen J, Liu F (2019) Baseline-covariate adjusted confidence interval for proportional difference between two treatment groups in clinical trials. Stat Biopharm Res 11:292–300CrossRef Chen J, Liu F (2019) Baseline-covariate adjusted confidence interval for proportional difference between two treatment groups in clinical trials. Stat Biopharm Res 11:292–300CrossRef
24.
Zurück zum Zitat Fleiss J (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76:378–382CrossRef Fleiss J (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76:378–382CrossRef
25.
Zurück zum Zitat Hum SW, Shaikh N (2019) Risk factors for delayed antimicrobial treatment in febrile children with urinary tract infections. J Pediatr 205:126–129CrossRef Hum SW, Shaikh N (2019) Risk factors for delayed antimicrobial treatment in febrile children with urinary tract infections. J Pediatr 205:126–129CrossRef
26.
Zurück zum Zitat Shaikh N, Mattoo TK, Keren R, Ivanova A, Cui G, Moxey-Mims M, Majd M, Ziessman HA, Hoberman A (2016) Early antibiotic treatment for pediatric febrile urinary tract infection and renal scarring. JAMA Pediatr 170:848–854CrossRef Shaikh N, Mattoo TK, Keren R, Ivanova A, Cui G, Moxey-Mims M, Majd M, Ziessman HA, Hoberman A (2016) Early antibiotic treatment for pediatric febrile urinary tract infection and renal scarring. JAMA Pediatr 170:848–854CrossRef
27.
Zurück zum Zitat Shaikh N, Craig JC, Rovers MM, Da Dalt L, Gardikis S, Hoberman A, Montini G, Rodrigo C, Taskinen S, Tuerlinckx D, Shope T (2014) Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data. JAMA Pediatr 168:893–900CrossRef Shaikh N, Craig JC, Rovers MM, Da Dalt L, Gardikis S, Hoberman A, Montini G, Rodrigo C, Taskinen S, Tuerlinckx D, Shope T (2014) Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data. JAMA Pediatr 168:893–900CrossRef
Metadaten
Titel
Corticosteroids to prevent kidney scarring in children with a febrile urinary tract infection: a randomized trial
verfasst von
Nader Shaikh
Timothy R. Shope
Alejandro Hoberman
Gysella B. Muniz
Sonika Bhatnagar
Andrew Nowalk
Robert W. Hickey
Marian G. Michaels
Diana Kearney
Howard E. Rockette
Martin Charron
Ruth Lim
Massoud Majd
Eglal Shalaby-Rana
Marcia Kurs-Lasky
Daniel M. Cohen
Ellen R. Wald
Greg Lockhart
Hans G. Pohl
Judith M. Martin
Publikationsdatum
15.06.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 11/2020
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-020-04622-3

Weitere Artikel der Ausgabe 11/2020

Pediatric Nephrology 11/2020 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.